

Clinical Trial Protocol

Iranian Registry of Clinical Trials

29 Jul 2026

The effect of N-acetyl cysteine in preventing the incidence and severity of mucositis in patients undergoing bone marrow transplantation

Protocol summary

Summary

Our purpose in this double blinded randomized study is to evaluate the N-acetyl cysteine effect on mucositis prevention in patient with acute myeloid leukemia (AML) & acute lymphoblastic leukemia (ALL) & Myelodysplastic syndrome (MDS) whose received Busulfan and/or Cyclophosphamide before Hematopoietic stem cell transplantation (HSCT) in Shariati Teaching Hospital, Tehran, Iran. Sixty-four patients will be randomized in two groups with balanced block randomization method. One group will receive N-acetyl cysteine IV(100mg/kg) and another group will receive placebo per day. Therapy will start on the morning before starting chemotherapy and will continue until day +15. Response assessment will include: Mucositis, glutathione peroxidase levels in the serum and infectious complications.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201303301030N13**

Registration date: **2013-04-10, 1392/01/21**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2013-04-10, 1392/01/21

Registrant information

Name

Mahdi Jalili

Name of organization / entity

Hematology-Oncology & SCT Research Center

Country

Iran (Islamic Republic of)

Phone

+98 21 8490 2662

Email address

m_jalili@farabi.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Hematology-Oncology and SCT Research Center

Expected recruitment start date

2012-11-05, 1391/08/15

Expected recruitment end date

2013-06-05, 1392/03/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of N-acetyl cysteine in preventing the incidence and severity of mucositis in patients undergoing bone marrow transplantation

Public title

The effect of N-acetyl cysteine in preventing mucositis in patients undergoing bone marrow transplantation

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: 1- Patients receiving chemotherapy regimens (Endoxane- busulfan) in bone marrow transplantation. 2- The patient over the 18 years old of age. 3-Informed consent forms signed by the patients. Exclusion: 1- Participating in other clinical trial (drug or supplement) 2- Dissatisfaction of patient.

Age

From **18 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: 64

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Hematology-Oncology and SCT Research Center
Ethics Committee

Street address

Shariati Hospital, Kargar Ave

City

Tehran

Postal code

Approval date

2012-07-01, 1391/04/11

Ethics committee reference number

91/4/11

Health conditions studied

1

Description of health condition studied

Mucositis (oral)

ICD-10 code

K12.3

ICD-10 code description

Oral mucositis (ulcerative)

2

Description of health condition studied

AML

ICD-10 code

C92.0

ICD-10 code description

Acute myeloblastic leukaemia

3

Description of health condition studied

ALL

ICD-10 code

C91.0

ICD-10 code description

Acute lymphoblastic leukaemia

4

Description of health condition studied

MDS

ICD-10 code

D46

ICD-10 code description

Myelodysplastic syndromes

Primary outcomes

1

Description

Oral mucositis

Timepoint

Daily at the first day of chemotherapy until the patients
discharged

Method of measurement

Clinical observation

Secondary outcomes

1

Description

Glutathione peroxidase serum level

Timepoint

At the first day of admission and 14 days after the
transplantation

Method of measurement

Lab Test (ng/dl)

2

Description

Fever incidence

Timepoint

Daily until discharg

Method of measurement

Measurement of oral temperature

3

Description

Duration of neutropenia

Timepoint

Daily until discharg

Method of measurement

Lab Test

4

Description

Consumption of TPN
Timepoint
During Hospitalization
Method of measurement
Medical Records

5

Description
Antibiotic consumption
Timepoint
During Hospitalization
Method of measurement
Medical Records

Intervention groups

1

Description
N-acetyl cysteine IV 00mg/kg daily
Category
Treatment - Drugs

2

Description
Placebo
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Hematology-Oncology and SCT Research Center
Full name of responsible person
Amirhossein Moslehi
Street address
Shariati Hospital, Kargar Ave
City
Tehran

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Hematology Oncology and SCT Research Center
Full name of responsible person
Zohreh Shahabi
Street address
Shariati Hospital, Kargar Ave
City
Tehran
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?

Yes
Title of funding source
Hematology Oncology and SCT Research Center
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Hematology Oncology and SCT Research Center
Full name of responsible person
Amirhossein Moslehi
Position
ParmD
Other areas of specialty/work
Street address
Shariati Hospital, Kargar Ave
City
Tehran
Postal code
Phone
+98 21 8490 2635
Fax
Email
horcbmt@tums.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Hematology Oncology and SCT Research Center
Full name of responsible person
Molok Hajibabaei
Position
Clinical pharmacy /associated prof
Other areas of specialty/work
Street address
Shariati Hospital, Kargar Ave
City
Tehran
Postal code
Phone
+98 21 8490 2635
Fax
Email
horcbmt@tums.ac.ir
Web page address

Person responsible for updating data

Contact

Name of organization / entity

Hematology-Oncology and SCT Research Center

Full name of responsible person

Mahdi Jalili

Position

MD

Other areas of specialty/work**Street address**

Shariati Hospital, Kargar Ave

City

Tehran

Postal code**Phone**

+98 21 8490 2635

Fax**Email**

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty